Key clinical studies of Regeneron's ARCALYST (rilonacept) for treatment of CAPS published
Regeneron's ARCALYST (rilonacept) has been shown to effectively manage symptoms of Cryopyrin-Associated Periodic Syndromes (CAPS), a rare inherited disease. The treatment demonstrated an 84% improvement in overall symptom scores and high patient response rates.